Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 729

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 729
---
 the Years Ended December                
 31, 2024 and 2023                                                                 |     | F-70 |
| Consolidated Statements of Stockholders’ Equity (Deficit) for the Years           
 Ended December 31, 2024 and 2023                                                  |     | F-71 |
| Consolidated Statements of Cash Flows for the Years Ended December                
 31, 2024 and 2023                                                                 |     | F-73 |
| Notes to the Consolidated Financial Statements                                    |     | F-74 |
| KINETA FINANCIAL STATEMENTS                                                       |     |      |
| Report of Independent Registered Public Accounting Firm                           |     | F-93 |
| Consolidated Balance Sheets as of December 31, 2024 and                           
 2023                                                                              |     | F-95 |
| Consolidated Statements of Operations for the Years Ended December                
 31, 2024 and 2023                                                                 |     | F-96 |
| Consolidated Statements of Stockholders’ Equity (Deficit) for the Years           
 Ended December 31, 2024 and 2023                                                  |     | F-97 |
| Consolidated Statements of Cash Flows for the Years Ended December                
 31, 2024 and 2023                                                                 |     | F-98 |
| Notes to the Consolidated Financial Statements                                    |     | F-99 |

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of

Kintara Therapeutics, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Kintara Therapeutics, Inc. (the “Company”) as of June 30, 2024 and 2023, the
related consolidated statements of operations, stockholders’ equity and cash flows for each of the two years in the period ended June 30, 2024, and the related notes (collectively referred to as the “financial statements”). In
our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period
ended June 30, 2024, in conformity with accounting principles generally accepted in the United States of America.

Explanatory Paragraph – Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a
going concern. As